Picotamide
Picotamide structure
|
Common Name | Picotamide | ||
|---|---|---|---|---|
| CAS Number | 32828-81-2 | Molecular Weight | 376.40900 | |
| Density | 1.246g/cm3 | Boiling Point | 668.1ºC at 760mmHg | |
| Molecular Formula | C21H20N4O3 | Melting Point | 124ºC | |
| MSDS | Chinese USA | Flash Point | 357.8ºC | |
|
Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
Thromb. Haemost. 78(5) , 1385-91, (1997) Picotamide is a dual thromboxane (Tx) A2 receptor antagonist/Tx synthase inhibitor although some observations suggest an anti-vasoconstrictor effect independent of TxA2 inhibition/antagonism. The aim of our study was to assess whether picotamide antagonises v... |
|
|
Determinants of fibrinogen in an Italian population suffering from claudication. Lower fibrinogen in the south compared to middle and north of Italy. The ADEP Group.
Haematologica 83(8) , 701-7, (1998) Prospective studies have shown that high plasma levels of fibrinogen are independently associated with the risk of cardiovascular complications. In patients suffering from peripheral vascular disease (PVD) fibrinogen has been shown to be an independent predic... |
|
|
Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure.
J. Am. Coll. Cardiol. 42(1) , 133-9, (2003) The aim of this study was to evaluate whether thromboxane inhibition can favorably affect renal perfusion and clinical conditions in patients affected by severe heart failure.The renal formation of the vasoconstrictor thromboxane A(2) (TxA(2)) is increased du... |
|
|
8-isoprostane F2α up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide.
BJU Int. 106(11) , 1794-8, (2010) To explore the possible role of of 8-isoprostane F(2α) (8-IPF(2α) ) in the aetiology of erectile dysfunction (ED), as the over-production of superoxide (O(2)(-)) derived from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase results in the formation... |
|
|
Treatment of aura: solving the puzzle.
Neurol. Sci. 27 Suppl 2 , S96-9, (2006) Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, which may trigger auras, and abnormal platelet behaviour, which cons... |
|
|
The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.
Am. J. Physiol. Renal Physiol. 305(10) , F1383-90, (2013) Inhibition of prostate smooth muscle contraction is an important strategy for medical treatment of lower urinary tract symptoms (LUTS). Besides α1-adrenoceptors, prostate smooth muscle contraction is induced by activation of thromboxane (TXA2) receptors (TXA2... |
|
|
Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat.
Prostaglandins Leukot. Essent. Fatty Acids 65(2) , 91-7, (2001) Two currently available edible oils-olive and canola-and two oil blends of plant origin having different n-3/n-6 polyunsaturated fatty acid (PUFA) ratios were evaluated for their ability to modify vascular dysfunction in the spontaneously hypertensive rat (SH... |
|
|
Picotamide in migraine aura prevention: a pilot study.
Neurol. Sci. 25 Suppl 3 , S267-9, (2004) In an open, preliminary trial we evaluated the use of picotamide, an antiplatelet drug, in the prophylactic treatment of migraine aura (MA). Twenty-two women suffering from migraine with typical aura or MA without headache, diagnosed according to Internationa... |
|
|
Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study.
J. Int. Med. Res. 26(4) , 200-5, (1998) In a controlled, randomized, 6-year trial the safety and efficacy of picotamide, a dual-action antithromboxane agent, were assessed in 50 patients with type 2 diabetes mellitus at increased risk of thrombotic vascular events. The patients were randomized to t... |
|
|
Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides.
Bioorg. Med. Chem. Lett. 22(21) , 6591-5, (2012) On the purpose of searching for the structure-activity relationship (SAR) and obtaining novel anti-platelet drugs, 41 4-methoxybenzene-1,3-isophthalamides have been described the synthesis process and in vitro activities on anti-platelet aggregation. The targ... |